Codiak BioSciences has filed to raise $82.5 million in an IPO.
The firm is advancing a pipeline of exosome-based treatment candidates for cancer and other diseases.
CDAK has developed significant collaboration partnerships with major pharma firms and the IPO appears priced within the typical range for biopharma companies.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,